PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
• Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo
• Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors
• Data is currently being presented at the AACR Virtual Annual Meeting 2021
OXFORD, UK & CAMBRIDGE, Mass./USA – PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021. The study, “T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts”, assessed anti-tumor synergy between PsiOxus’ T-SIGn® vectors and an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR)-T cell therapy from bluebird bio in xenograft lung tumors.